iECURE Announces Updated Safety And Metabolic Control Data From Phase 1/2 Trial Of ECUR-506 In Neonatal-Onset OTC Deficiency To Be Presented August 27 At SSIEM Symposium

CPTx appoints Matt Kane as Chief Financial Officer

CPTx announced the appointment of Matt Kane as Chief Financial Officer. Kane brings extensive experience in gene editing and cell therapy, with a track record of raising over $500 million in equity financing and securing strategic partnerships valued at over $4 billion. He previously served as CEO of Celyad Oncology, Tune Therapeutics, and Precision Biosciences. Kane will lead CPTx's financing and partnering activities as the company advances its non-viral DNA-based in vivo CAR T therapies toward clinical studies.

iECURE Says Updated OTC-HOPE Low-Dose Data Showed 74% Reduction In Annualized Hyperammonemic Crises, 57% Reduction In Hyperammonemic Events; Completes Phase 1/2 Dosing Across All Three Cohorts

iECURE, a private clinical-stage genome editing company, reported preliminary safety observations from all nine participants dosed with ECUR-506 across the low-, intermediate- and high-dose cohorts, saying the therapy

Precision BioSciences Doses First Patient In The Phase 1/2 Function-DMD Clinical Trial Evaluating PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy

8-K filing — PRECISION BIOSCIENCES INC (DTIL)

Filed: 2026-08-24 AccNo: 0001628280-26-058512 Size: 177 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits